Last edition
News about "anti-CD38 monoclonal antibodies"
CASI Pharmaceuticals Plans to Submit IND Application For CID-103
CASI Pharmaceuticals, Inc. has planned to submit an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for CID-103 for the treatment of antibody-mediated rejection (AMR) in kidney transplant recipients by the end of 2024.
Anti-CD38 Monoclonal Antibodies | 28/06/2024 | By Aishwarya | 428
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members